BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38176400)

  • 1. Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas.
    Fardella E; Zanirato G; Magni M; Caldarelli N; Chiappella A; Dodero A; Ljevar S; Orsucci L; Re A; Usai SV; Stefoni V; Castellino C; Rossi FG; Pinto A; Carniti C; Corradini P
    Br J Haematol; 2024 May; 204(5):1752-1756. PubMed ID: 38176400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
    Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas.
    Kaito S; Kanemasa Y; Sasaki Y; Okuya T; Yamaguchi T; Funasaka C; Shimoyama T; Omuro Y; Hishima T; Maeda Y
    Int J Hematol; 2018 Apr; 107(4):451-459. PubMed ID: 29103138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
    Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
    Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma.
    Wei C; Wang W; Zhang Y; Zhao D; Zhang W; Zhou D
    Br J Haematol; 2023 Jul; 202(1):86-95. PubMed ID: 37132364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas.
    Hur JY; Kim YJ; Yoon SE; Son DS; Park WY; Kim SJ; Park D; Kim WS
    Ann Hematol; 2020 Jun; 99(6):1293-1302. PubMed ID: 32296914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
    Valpione S; Gremel G; Mundra P; Middlehurst P; Galvani E; Girotti MR; Lee RJ; Garner G; Dhomen N; Lorigan PC; Marais R
    Eur J Cancer; 2018 Jan; 88():1-9. PubMed ID: 29175734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum.
    Akagi T; Takahashi N; Yamaguchi K; Ishizawa K; Murai K; Tajima K; Ikeda K; Kameoka Y; Kameoka J; Ito S; Kato Y; Noji H; Shichishima T; Itoh J; Ichinohasama R; Harigae H; Ishida Y; Sawada K
    J Clin Exp Hematop; 2011; 51(1):29-35. PubMed ID: 21628858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified.
    Beltran BE; Aguilar C; Quiñones P; Morales D; Chavez JC; Sotomayor EM; Castillo JJ
    Leuk Lymphoma; 2016; 57(1):58-62. PubMed ID: 25926063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
    Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas.
    Haverkos BM; Huang Y; Gru A; Pancholi P; Freud AG; Mishra A; Ruppert AS; Baiocchi RA; Porcu P
    Int J Cancer; 2017 Apr; 140(8):1899-1906. PubMed ID: 27943278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
    Shibata Y; Hara T; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Goto N; Nannya Y; Ito H; Kito Y; Miyazaki T; Takeuchi T; Saito K; Seishima M; Takami T; Moriwaki H; Shimizu M; Tsurumi H
    Hematol Oncol; 2017 Dec; 35(4):637-644. PubMed ID: 27338762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
    Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
    Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
    Ellin F; Landström J; Jerkeman M; Relander T
    Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas.
    Watanabe T; Kinoshita T; Itoh K; Yoshimura K; Ogura M; Kagami Y; Yamaguchi M; Kurosawa M; Tsukasaki K; Kasai M; Tobinai K; Kaba H; Mukai K; Nakamura S; Ohshima K; Hotta T; Shimoyama M
    Leuk Lymphoma; 2010 May; 51(5):813-21. PubMed ID: 20367565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
    Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
    Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.
    Jung SH; Ahn JS; Kim YK; Kweon SS; Min JJ; Bom HS; Kim HJ; Chae YS; Moon JH; Sohn SK; Lee SW; Byun BH; Do YR; Lee JJ; Yang DH
    BMC Cancer; 2015 Mar; 15():198. PubMed ID: 25879747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
    Tomita N; Motomura S; Hyo R; Takasaki H; Takemura S; Taguchi J; Fujisawa S; Ogawa K; Ishigatsubo Y; Takeuchi K
    Cancer; 2007 Mar; 109(6):1146-51. PubMed ID: 17311304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.
    Kato A; Imai Y; Aoki K; Tabata S; Matsushita A; Hashimoto H; Takahashi T; Ishikawa T
    Ann Hematol; 2014 Jul; 93(7):1185-91. PubMed ID: 24526138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aggressive peripheral T-cell lymphomas: 2015.
    Armitage JO
    Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.